Sartorius Stedim Biotech SA
PAR:DIM
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
145.35
280
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA
Cash Taxes Paid
Sartorius Stedim Biotech SA
Cash Taxes Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Taxes Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sartorius Stedim Biotech SA
PAR:DIM
|
Cash Taxes Paid
€175.5m
|
CAGR 3-Years
6%
|
CAGR 5-Years
22%
|
CAGR 10-Years
21%
|
|
|
Pcas SA
PAR:PCA
|
Cash Taxes Paid
€2.2m
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Eurofins-Cerep SA
PAR:ALECR
|
Cash Taxes Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sartorius Stedim Biotech SA
Glance View
Sartorius Stedim Biotech SA, a key player in the biopharmaceutical industry, has positioned itself at the forefront of innovation in bioprocessing and laboratory solutions. Established in the early 2000s through the merger of Sartorius AG's biotech division and Stedim S.A., the company’s mission centers on enabling the development and production of life-saving biologics. With a comprehensive portfolio that includes bioprocessing equipment, research services, and laboratory instruments, Sartorius caters to a vast array of customers, from small biotech firms to large pharmaceuticals, ensuring seamless workflows in drug development and manufacturing. By leveraging cutting-edge technologies and maintaining a commitment to sustainability, Sartorius has built a reputation as a trusted partner in the industry, addressing the growing demand for effective therapies amidst an ever-evolving healthcare landscape. As the global biopharmaceutical market expands, driven by advancements in personalized medicine and precision therapies, Sartorius is well-positioned to capitalize on these trends. The company’s recent strategic acquisitions and investments in digitalization and automation enhance its product offerings, allowing clients to improve efficiencies and reduce time-to-market for essential therapeutics. Boasting a strong financial track record and a commitment to research and development, Sartorius Stedim Biotech SA not only ensures consistent growth but also aligns with long-term health sector trends. For investors, this combination of strategic vision, robust market position, and innovative capabilities makes Sartorius an attractive investment opportunity in the booming biotechnology sector.
See Also
What is Sartorius Stedim Biotech SA's Cash Taxes Paid?
Cash Taxes Paid
175.5m
EUR
Based on the financial report for Jun 30, 2024, Sartorius Stedim Biotech SA's Cash Taxes Paid amounts to 175.5m EUR.
What is Sartorius Stedim Biotech SA's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 10Y
21%
Over the last year, the Cash Taxes Paid growth was -17%. The average annual Cash Taxes Paid growth rates for Sartorius Stedim Biotech SA have been 6% over the past three years , 22% over the past five years , and 21% over the past ten years .
You don't have any saved screeners yet
